Key facts
- It has raised $28.9M across 3 recorded rounds; the latest was Seed Round ($1.0M) in Jun 2025.
- Notable investors include National Institutes of Neurological Disorders and Stroke.
- Armis Biopharma has filed 4 Form Ds with the SEC since 2018, most recently Jul 2025 ($1.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Armis Biopharma
Funding rounds
3 roundsAbout Armis Biopharma
Developer of non-systemic antimicrobial products intended to protect against resistant pathogens and chemical/biological warfare agents. The company's platform is a proprietary peracid/hydrogen peroxide-based non-systemic antimicrobial agent and has been independently verified to eliminate a wide range of bacterial, viral, fungal, and toxic agent threats, enabling organizations to serve a variety of markets, including healthcare, defense, and industry.
- Sector
- Healthcare
- HQ
- Fort Collins, CO, United States
- Founded
- 1997
- Employees
- 10
- Website
- armisbiopharma.com/
- Ownership
- Privately Held (backing)
Armis Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Armis Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Armis Biopharma in its N-PORT filings yet. We sweep new filings monthly.